Technology assessment of digital health applications for reimbursement decisions

被引:4
|
作者
Jeindl, Reinhard [1 ]
Wild, Claudia [1 ]
机构
[1] Austrian Inst Hlth Technol Assessment GmbH AIHTA, Garnisongasse 7-20, A-1090 Vienna, Austria
关键词
Digital Health Applications; Assessment Frameworks; Reimbursement; MHealth; Digital Health; MODEL;
D O I
10.1007/s10354-021-00881-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background For most digital health applications (DiGA) only limited evidence of benefit is available. Currently available assessment frameworks do not cover all domains of a full health technology assessment (HTA). Additionally, technology-specific aspects are required for the evaluation of DiGA. This work aimed to analyze the available assessment frameworks and design an evaluation process for DiGA. Methods By a systematic literature search six assessment frameworks for DiGA were selected and analyzed. A hand search for strategies on DiGA of selected countries was conducted. Results Of the analyzed assessment frameworks four described study designs. One assessment framework proposed a risk classification of DiGA. Aspects of artificial intelligence were assessed by one assessment framework. The analyzed countries have differing strategies for reimbursement of DiGA. Conclusion Assessment frameworks for DiGA are very heterogeneous. There are efforts to find regulations for DiGA on a national level. When evaluating DiGA, a staged approach considering risk classes with subsequent evaluation of relevant HTA aspects is recommended.
引用
收藏
页码:44 / 52
页数:9
相关论文
共 50 条
  • [1] AGENCY AGREEMENT IN HEALTH TECHNOLOGY ASSESSMENT REIMBURSEMENT DECISIONS
    Jaksa, A.
    Demb, J.
    Ho, Y. S.
    Daniel, K.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A3 - A3
  • [2] Technologiebewertung digitaler Gesundheitsanwendungen für RefundierungsentscheidungenTechnology assessment of digital health applications for reimbursement decisions
    Reinhard Jeindl
    Claudia Wild
    [J]. Wiener Medizinische Wochenschrift, 2024, 174 : 44 - 52
  • [3] Use of health technology assessment in drug reimbursement decisions in China
    Chen, Wen
    Zhang, Luying
    Hu, Min
    Hu, Shanlian
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2023, 381
  • [4] VARIATION IN HEALTH TECHNOLOGY ASSESSMENT AND REIMBURSEMENT DECISIONS IN ENGLAND, FRANCE, AND GERMANY: SPOTLIGHT ON THE IMPACT OF UNCERTAINTY
    Horscroft, J. A.
    Chapman, A.
    Philips, Z.
    Akehurst, R.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A468 - A468
  • [5] Description of the use of multicriteria to support pricing and reimbursement decisions by European health technology assessment bodies
    David Elvira
    Mercè Obach
    Caridad Pontes
    [J]. BMC Health Services Research, 21
  • [6] Capacity Building for Health Technology Assessment in Jordan: Institutionalization and Its Use in Pricing and Reimbursement Decisions
    Almomani, Emad
    Hammad, Eman A.
    AlQutob, Raeda
    Abu Hammour, Khawla
    Al-Sharu, Emad
    Abu-Shaer, Muien
    Alabbadi, Ibrahim
    Kalo, Zoltan
    [J]. VALUE IN HEALTH REGIONAL ISSUES, 2022, 32 : 47 - 53
  • [7] THE PATIENT PERSPECTIVE IN HEALTH TECHNOLOGY ASSESSMENT REIMBURSEMENT DECISIONS FOR ORPHAN DRUGS ACROSS DIFFERENT COUNTRIES
    Nicholson, L.
    Langham, S.
    Adkins, E.
    [J]. VALUE IN HEALTH, 2019, 22 : S860 - S860
  • [8] Description of the use of multicriteria to support pricing and reimbursement decisions by European health technology assessment bodies
    Elvira, David
    Obach, Merce
    Pontes, Caridad
    [J]. BMC HEALTH SERVICES RESEARCH, 2021, 21 (01)
  • [9] DOES USING CLINICAL TRIALS IN HEALTH TECHNOLOGY ASSESSMENT (HTA) ECONOMIC MODELLING IMPACT REIMBURSEMENT DECISIONS?
    Inumerable, R. V. F.
    Rubinstein, J.
    [J]. VALUE IN HEALTH, 2020, 23 : S139 - S139
  • [10] Reimbursement of biosimilars in Poland: is there a link to health technology assessment?
    Neumann, Dominika
    Jablecka, Anna
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2016, 16 (06) : 781 - 792